Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan


	Probabilistic analysis.

Part of: Dadanbekova D, Zhakipbekov K, Kodasbayev A, Datkhayev U, Petrova G, Tachkov K (2024) Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan. Pharmacia 71: 1-6. https://doi.org/10.3897/pharmacia.71.e115952